Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-21
2006-11-21
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S242000, C544S284000, C514S365000, C548S146000
Reexamination Certificate
active
07138403
ABSTRACT:
This invention concerns the use of a compound of formula (I)a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl or C1-6alkyloxy; polyhaloC1-4alkyl; C1-4alkyloxy; cyano; amino; aminocarbonyl; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; H2N—S(═O)2—; mono- or di(C1-6alkyl)amino-S(═O)2; —C(═N—Rx)NRyRz; Q is an optionally substituted carbocycle or an optionally substituted heterocycle; L is substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of diseases mediated through TNF-α and/or IL-12.
REFERENCES:
patent: 3933838 (1976-01-01), Manghisi et al.
patent: 5240929 (1993-08-01), Connor et al.
patent: 6231786 (2001-05-01), Wingen et al.
patent: 6531479 (2003-03-01), Wang et al.
patent: 1 959 307 (1969-11-01), None
patent: 258 165 (1987-03-01), None
patent: 117 082 (1984-08-01), None
patent: 1 189 008 (1970-04-01), None
patent: 3 144 612 (1992-12-01), None
patent: WO 96/03392 (1996-02-01), None
patent: WO 97/05131 (1997-02-01), None
patent: WO 98/01449 (1998-01-01), None
patent: WO 98/08830 (1998-03-01), None
patent: WO 98/08841 (1998-03-01), None
patent: WO 00/35911 (2000-06-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/64674 (2001-09-01), None
patent: WO 02/50047 (2002-06-01), None
patent: WO 02/50048 (2002-06-01), None
patent: WO 02/059098 (2002-08-01), None
patent: WO 02/062774 (2002-08-01), None
Simiti et al, “Synthese und antibakterielle Wirkung von 2-Aryl-4-R-5-glyoxyloyl-thiazolen,” Arch. Pharm. (Weinheim) 314, 744-750 (1981).
Simiti, I. et al., Synthese und antibakterielle Wirkung von 2-Aryl-4-R-5-glyoxyloyl-thiazolen, Arch. Pharm. (Weinheim) 314, pp. 744-750 (1981).
Benko, A. et al., “4-Methyl-2-[p-nitro-phenyl]-5-diazoacetyl-thiazol, ein neues, sehr stabiles Diazoketon.”Chem. Ber. 1967, pp. 2184-2187, vol. 100, No. 7+.
Kempter, G. et al., “Thiazolyl- und Pyrrolytchinoline1)2).”Z. Chem., 9. Jg., 1969, pp. 186-187, vol. 5, No. 9.
Csavassy, G. et al., “Synthese und Umsetzung von 2-Aryly-5-diazoacetyl-4-methyl-thiazolen.”Justus Liebigs Ann. Chem., 1974, pp. 1195-1205.
Sawhney, S. N. et al., “Thiazole Derivatives: Part I-Synthesis & Anti-inflammatory Activity of Some 2′-Alkyl/Aryl-2-aryl-4-methyl-4′, 5-bithiazolyls & 2′-Amino/Substitutedamino-2-aryl-4-methyl-4′,5-bithiazolyls.”Indian J. Chem., 1976, pp. 552-555, vol. 14B.
Sarodnick G. et al., “Heterocyclisch Substituierte Thiazole als Thiabendazol-Analoge.”Z. Chem. 1979, pp. 21-22. vol. 1, No. 19.
Simiti, I, et al., “Synthase Und antibakterielle Wirkung von 2-Aryl-4-R-5-glyxyloyl-thiazolen.”Arch. Pharm., 1981, pp. 744-750, vol. 9, No. 314.
Yousif, M. M., “Studies on Tertiary Amine Oxides. LXXIV.′) Reactions of Aromatic N-Oxides with 2-Phenyl-2-Thiazolin-4-one in the Presence of Acetic Anhydride.”Chem. Pharm. Bull., 1982, pp. 174-179, vol. 30(6).
Burger, K. et al., “Zum Reaktionsverhalten von Trifluormethyl-Gruppen Synthese von 1,3-Azolen aus Trifluormethyl-substituierten Hetero-1,3-dienen.”Chem. Ber., 1982, pp. 2494-2507, vol. 115.
Moriya, T. et al., “Synthesis of Ethyl 2-(4-Chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, A Hypolipedmic Agent, and Related Compounds1.”J. Med. Chem. 1988, pp. 1197-1204, vol. 31, No. 6.
Burger, K., et al., “Uber eine neue Methode zur positionsselektiven Einfuhrung von Trifluormethyl-Gruppen in Heteroaromaten, Teil 2. 'Nucleophile Substitution an 5-fluor-4-trifluormethyl-substituierten 1,3-Azolen.”Synthesis, 1988, pp. 194-198, vol. 3.
Burger, K., et al., “Zum Cyloadditionsverhalten von 5-Azido-4-trifluormethyl-1, 3-azolen.”Z. Naturforsch, B. Chem. Sci., 1990, pp. 1695-1708, vol. 12, No. 45.
PCT International Search Report for PCT Appln. No. PCT/EP02/08956, mailed Aug. 9, 2003 which relates to this corresponding U.S. Appl. filed herewith.
Cooymans Ludwig Paul
De Brabander Marc J.
Diels Gaston Stanislas Marcella
Goncharenko Mykhalyo
Love Christopher John
Chung Susannah L.
Dodd Thomas
Janssen Pharmaceutica N.V.
Saeed Kamal
LandOfFree
2,4,5-trisubstituted thiazolyl derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4,5-trisubstituted thiazolyl derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4,5-trisubstituted thiazolyl derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695466